Report cover image

Myasthenia Gravis

Publisher Reach Market Research
Published Nov 23, 2022
Length 31 Pages
SKU # RMR19136505

Description

MarketVue®: Myasthenia Gravis

The MarketVue®: Myasthenia Gravis market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: Myasthenia Gravis report is supported by 5 qualitative interviews with key opinion leaders, a quantitative survey with 26 U.S. physicians and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• UCB
• Immunovant
• Janssen
• Alexion/Astrazeneca
• Regeneron
• Sanofi
• Hoffmann-La Roche
• RemeGen
• NMD Pharma
• Cartesian Therapeutics
• Cabaletta Bio
• IASO Bio

Key drugs mentioned:
• Rituximab
• Eculizumab (Soliris)
• Efgartigimod (Vyvgart)
• Ravulizumab (Ultomiris)
• Pyridostigmine (Mestinon)
• Mycophenolate
• Azathioprine
• Rozanolixizumab (Rystiggo)
• Batoclimab
• Nipocalimab / M281
• Zilucoplan (Zilbrysq) / RA101495
• Gefurulimab / ALXN1720
• Pozelimab (Veopoz) + Cemdisiran
• Satralizumab (Enspryng)
• Inebilizumab (Uplizna)
• Tolebrutinib
• Telitacicept
• NMD670
• Vemircopan / ALXN2050
• Descartes-08
• MuSK-CAART
• CT103A + Cyclophosphamide + Fludarabine

Please note: the online download version of this report is for a global site license.

Table of Contents

31 Pages
1. DISEASE OVERVIEW
A rare, chronic, autoimmune disease marked by muscle weakness and fatigue
Figure 1.1. Select clinical manifestations of MG
FcRn inhibition, B-cell directed therapies, and the complement pathway are common drug targets
Figure 1.2 MG drugs targets in AChR+ patients
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1. Diagnosed prevalent cases of MG by region
Table 2.1 Diagnosed prevalent and drug-treated patients in the US and EU5
3. DIAGNOSIS & CURRENT TREATMENT
Overview
Figure 3.1. Diagnostic pathway for MG patients
Diagnostic testing for auto-antibodies is standard and disease severity criteria for MG are clearly defined
Table 3.1. MGFA Clinical Classification
Figure 3.2. Neurologist-reported percentage of MG patients misdiagnosed/not diagnosed in a timely manner
Figure 3.3. Neurologist-reported percentage of their patients in each clinical category
Improvement of symptoms and restoring patient’s baseline function and quality of life are the ultimate goals
Table 3.2. Treatment goals for MG
Figure 3.4. Neurologist-reported proportion of MG patients currently treated with drug therapy
Treatment flow for MG
There is no standard approach to treatment; biologics are emerging as key players in recent years
Figure 3.5. Neurologist-reported current treatment share for MG patients: 1st-line setting
Figure 3.6. Neurologist-reported % of patients not well-managed by first-line therapy
Figure 3.7. Neurologist-reported current treatment share for MG patients: 2nd-line and later settings
Upsides and downsides of current non-biologic MG treatments
Head-to-head comparison of FDA-approved biologics
Table 3.3. Comparison of approved biologics
Physician perspectives on current biologics
Table 3.4 . KOL insights on approved biologics
Cost, dosing convenience, and safety profile are the key factors that drive biologic choice
Table 3.5. KOL feedback on biologics based on key differentiators that drive treatment choice
With Argenx taking the lead, the race is on to develop more conveniently dosed biologics
Table 3.6. Summary of the ADAPT-SC trial results
Key treatment dynamics that will shape disease management and drug use in MG
Figure 3.7. Important dynamics of MG market evolution
4. UNMET NEED
Overview
Figure 4.1. Top unmet needs in MG
Figure 4.2. Neurologist-reported unmet needs in MG
High unmet needs persist despite three approved biologics for MG
5. PIPELINE ANALYSIS
Overview
Figure 5.1. Percentage of neurologists (n=26) rating target as “promising” for MG (score of 6 or 7)
The late-stage pipeline for MG is very active
Table 5.1. Key MG therapies in Phase 3
The late-stage pipeline for MG is very active
Table 5.1. Emerging MG therapies in Phase 3 (cont.)
Rozanolixizumab and zilucoplan are poised to be the latest entrants to the MG market
Figure 5.2. Phase 3 results for UCB’s Rozanolixizumab in MycarinG trial
Figure 5.3. Phase 3 results for UCB’s Zilucoplan in RAISE trial
The early-stage pipeline is also active and focused on largely similar mechanisms
Table 5.2. Notable MG therapies in Phase 1 / 2 Development
Neurologists’ opinions on the MG pipeline
6. VALUE & ACCESS
Overview
Table 6.1. Current MG therapy pricing, U.S.
Table 6.2. Typical U.S. commercial payer coverage ofrituximab for MG patients (Aetna, BCBS, Cigna, United)
Prior authorization criteria for biologics
Table 6.3. Typical U.S. commercial payer coverage of biologics for MG patients
Alexion and Argenx utilize patient support programs to expand access
Figure 6.1. Growth in lives covered through VBAs since launch of Vyvgart
7. METHODOLOGY
Primary market research approach
Epidemiology methodology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us